Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: a Phase 3, multicentre, double-blind, randomized study
about
Future challenges and treatment of Staphylococcus aureus bacteremia with emphasis on MRSAAntibiotic therapy for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) in non surgical woundsCommunity-associated methicillin-resistant Staphylococcus aureus: epidemiology and clinical consequences of an emerging epidemicCurrent concepts in antimicrobial therapy against select gram-positive organisms: methicillin-resistant Staphylococcus aureus, penicillin-resistant pneumococci, and vancomycin-resistant enterococciTigecycline : a critical safety reviewNewer antibacterial drugs for a new century.Pharmacokinetics and safety of recently approved drugs used to treat methicillin-resistant Staphylococcus aureus infections in infants, children and adults.Tigecycline use in critically ill patients: a multicentre prospective observational study in the intensive care setting.Systematic review and meta-analysis of the effectiveness and safety of tigecycline for treatment of infectious disease.A potential role for daptomycin in enterococcal infections: what is the evidence?MRSA: treating people with infection.Tissue penetration and pharmacokinetics of tigecycline in diabetic patients with chronic wound infections described by using in vivo microdialysis.The efficacy and safety of linezolid and glycopeptides in the treatment of Staphylococcus aureus infectionsAntibiotic management of methicillin-resistant Staphylococcus aureus--associated acute pulmonary exacerbations in cystic fibrosis.Colonization, pathogenicity, host susceptibility, and therapeutics for Staphylococcus aureus: what is the clinical relevance?Glycopeptide resistance in gram-positive cocci: a review.Excess deaths associated with tigecycline after approval based on noninferiority trials.Systematic review and network meta-analysis of tedizolid for the treatment of acute bacterial skin and skin structure infections caused by MRSA.Risk factors for Candida colonization and Co-colonization with multi-drug resistant organisms at admission.Systematic review and meta-analysis of linezolid and daptomycin for treatment of vancomycin-resistant enterococcal bloodstream infections.Newer developments in the treatment of Gram-positive infections.Daptomycin versus other antimicrobial agents for the treatment of skin and soft tissue infections: a meta-analysis.Diagnosis and management of community-associated MRSA infections in children.Methicillin-resistant Staphylococcus aureus in community-acquired and health care-associated pneumonia: incidence, diagnosis, and treatment options.Resistant pathogen-associated skin and skin-structure infections: antibiotic options.Complicated skin and soft tissue infection.Antimicrobial resistance: Not community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA)! A clinician's guide to community MRSA - its evolving antimicrobial resistance and implications for therapy.Efficacy and safety of tigecycline: a systematic review and meta-analysis.Gram-Positive Bacterial Infections: Research Priorities, Accomplishments, and Future Directions of the Antibacterial Resistance Leadership Group.Resistance to Non-glycopeptide Agents in Serious Staphylococcus aureus Infections.The efficacy and safety of tigecycline for the treatment of bloodstream infections: a systematic review and meta-analysis.Variation in potency and spectrum of tigecycline activity against bacterial strains from U.S. medical centers since its approval for clinical use (2006 to 2012).Novel antibiotics for the treatment of Staphylococcus aureus.Trimethoprim-sulfamethoxazole versus vancomycin for severe infections caused by meticillin resistant Staphylococcus aureus: randomised controlled trial.Tigecycline in febrile neutropenic patients with haematological malignancies: a retrospective case documentation in four university hospitals.Eradication of drug resistant Staphylococcus aureus by liposomal oleic acidsMeta-analysis of randomized controlled trials of vancomycin for the treatment of patients with gram-positive infections: focus on the study designEditorial Commentary: Linezolid vs Daptomycin for Vancomycin-Resistant Enterococci: The Evidence Gap Between Trials and Clinical Experience.Clarification to the systematic review and meta-analysis involving tigecycline.Eradication of methicillin-resistant Staphylococcus aureus infection by nanoliposomes loaded with gentamicin and oleic acid.
P2860
Q22305769-683FA340-3CD4-450C-8E42-E5CF4742C02BQ24202424-E1CB598F-F8CD-48DD-9B13-CE3063BE3EB8Q24614464-47D01392-CBE6-4908-BC17-795B38E7F075Q26853465-CC901E1D-2CF2-4C61-A890-1B2D7FAAFCE6Q28254593-4DA9EAA1-60EC-4639-A024-0292673E68A4Q30433333-A56ACC75-693C-41F8-8BBD-DF0848BD80F9Q33657212-5A1EDC26-65D8-41DF-BC09-AABFF6E751E6Q33770721-D5282BDE-42A3-4980-BF33-C8A14AA70686Q33776590-0C2AB89B-C602-4BAC-986D-F7E908055E84Q33845776-38C94A14-3E50-4953-8BC1-739CF38D578EQ33850476-DC2E8C87-533E-4279-9693-89397609D249Q34309522-18D8B81F-A773-4620-A7D6-A1E3A6FCDA1DQ34618696-95E8E841-567A-4E3D-8876-6C0EA14EA02EQ35542062-F8BC0223-72AD-4C03-928E-5239BD8AF354Q35736907-7650724C-4C92-430B-BC2F-2A335484DE63Q36072225-7FF18CBE-550D-4016-9B98-807663879831Q36115632-35C62CC4-3733-4C78-9297-3BB9AF6272C0Q36243256-F3A846F1-3F55-43A6-90C5-762D406DAEF7Q36278602-1A5B1058-8A29-4C8B-BBCF-9A5DF52F92E8Q37263709-D8A441F0-CCED-4033-B0DC-425B44364977Q37636151-3613C3AB-AB14-4A70-9771-232D039FBE15Q37637758-31A2B9B3-9992-4C67-A6E1-A4EDF124B357Q37682916-E85296FF-23EB-4675-AFFA-17A913EABCCFQ37752231-5604A13B-0D34-47BA-95AE-B0680A36DEBBQ37785546-5C3ED8BA-CD61-4DB9-A38A-9FEB8C070A3CQ37793714-27397803-36A8-4AD4-86A8-7813483A5C9DQ37819539-A1B0656B-43C7-4A79-825A-264080BFEB1AQ37891606-1B9E80B5-A3C5-4148-9C15-8384AB16CD25Q38738512-7DF8707F-8019-424B-9688-40CB1FAC094BQ39016281-B6E8C16D-3C14-4112-A01F-C7F07DDD381DQ39222597-579006A5-C371-4DDA-885B-1CE28CFB64CAQ39683665-FB565017-A058-4E87-AE50-56A4B244DFBDQ39933945-CB718E2D-F744-46C7-9590-CD8A4F1A1A76Q40155946-39A8124F-D357-4A6F-AD67-D692E09A8077Q40236833-10CB42F3-E375-4733-92BC-701E2C7FE10AQ41731619-1B9CEF2E-2380-4D55-BE63-0DDBA18B1C4DQ42544277-0C14EF7F-C746-435B-9A8B-2BBA21BEB7DBQ42906203-4CC5866B-DF5F-4694-98EA-8F73C112AA15Q42931315-1B3EAA52-D1D1-45D7-8DF4-4303D1ECFAB4Q44773244-6A49F4D9-B29A-45B1-9B1D-80F2BF5DC8CC
P2860
Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: a Phase 3, multicentre, double-blind, randomized study
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Efficacy and safety of tigecyc ...... double-blind, randomized study
@en
Efficacy and safety of tigecyc ...... double-blind, randomized study
@nl
type
label
Efficacy and safety of tigecyc ...... double-blind, randomized study
@en
Efficacy and safety of tigecyc ...... double-blind, randomized study
@nl
prefLabel
Efficacy and safety of tigecyc ...... double-blind, randomized study
@en
Efficacy and safety of tigecyc ...... double-blind, randomized study
@nl
P2093
P2860
P356
P1476
Efficacy and safety of tigecyc ...... double-blind, randomized study
@en
P2093
307 Study Group
A Razbadauskas
C A Cooper
E J Ellis-Grosse
H Gandjini
I Florescu
P2860
P304
P356
10.1093/JAC/DKN250
P407
P478
62 Suppl 1
P577
2008-09-01T00:00:00Z